Details

Primerjava pogojev naložbenega življenjskega zavarovanja : diplomsko delo
ID Klančar, Miha (Author), ID Penger, Sandra (Mentor) More about this mentor... This link opens in a new window

URLURL - Presentation file, Visit http://www.cek.ef.uni-lj.si/u_diplome/klancar3174.pdf This link opens in a new window

Language:Slovenian
Keywords:Slovenija, zavarovalstvo, življenjsko zavarovanje, investicije, ponudba, komparacije, analiza
Work type:Undergraduate thesis
Typology:2.11 - Undergraduate Thesis
Organization:EF - School of Economics and Business
Place of publishing:Ljubljana
Publisher:[M. Klančar]
Year:2008
Number of pages:50 str.
PID:20.500.12556/RUL-12522 This link opens in a new window
UDC:368
COBISS.SI-ID:17658086 This link opens in a new window
Publication date in RUL:11.07.2014
Views:1464
Downloads:160
Metadata:XML DC-XML DC-RDF
:
KLANČAR, Miha, 2008, Primerjava pogojev naložbenega življenjskega zavarovanja : diplomsko delo [online]. Bachelor’s thesis. Ljubljana : M. Klančar. [Accessed 4 April 2025]. Retrieved from: http://www.cek.ef.uni-lj.si/u_diplome/klancar3174.pdf
Copy citation
Share:Bookmark and Share

Secondary language

Language:Unknown
Keywords:Slovenia, insurance, life insurance, investments, supply, comparisons, analysis

Similar documents

Similar works from RUL:
  1. Verification and comparison of serological assays for quantification of specific anti-SARS-CoV-2 antibodies
  2. Primerjava treh metod za dokazovanje specifičnih protiteles IGG proti virusu varicela zoster
  3. Comparison of efficiency of two methods for detection of IgG and IgM antibodies to protozoan Toxoplasma gondii
  4. Specific T cell response to SARS-CoV-2 In volunteers before and after vaccination
  5. SARS-CoV-2 virions or ubiquitous cell structures?
Similar works from other Slovenian collections:
  1. Covid-19 pulmonary pathology
  2. Covid-19
  3. Data from Slovenian COVID-19 tracker
  4. Neutralizing anti-interferon-[gamma] autoantibodies
  5. Gibalna/športna aktivnost otrok v času svetovne epidemije SARS-COV-2 (COVID-19)

Back